EWALD STEPHEN P sold $859K of MEDP

EWALD STEPHEN P (General Counsel & Corp. Secy.) sold 1,245 shares of Medpace Holdings, Inc. (MEDP) at $690.00 ($0.86M total) on 2026-10-29.

Original reporting
SEC EDGAR · EWALD STEPHEN P
Published Nov 2, 2026, 11:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 11:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The disclosed sale adds a data point for sentiment models; while modest, it may influence short‑term trading algorithms.

02

Market read

A routine insider sell with modest dollar value; limited trading relevance but worth noting for compliance and sentiment tracking.

03

What to watch

Potential upcoming corporate actions or earnings that prompted the insider to adjust holdings.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; a sale by a senior officer is routinely monitored by traders.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

General Counsel EWALD STEPHEN P sold 1,245 MEDP shares for $859,050 on 2026-10-29, reducing his holding to 19,098 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The sale size ($859k) is modest but the insider is a senior officer; such transactions often prompt short‑term caution.

Market effects

Minimal impact on the broader biotech/clinical‑trial services sector.

No significant regional effect; confined to MEDP shareholders.

Limited to investors tracking insider activity.

Counterpoint

The sale could be unrelated to company fundamentals and merely a personal liquidity need, so price impact may be negligible.

Key entities

  • Medpace Holdings, Inc.

    NASDAQ‑listed contract research organization (ticker MEDP).

  • Ewald Stephen P.

    General Counsel & Corporate Secretary of Medpace, reporting an insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.